Birdwatch Note
2023-09-25 22:01:19 UTC - MISINFORMED_OR_POTENTIALLY_MISLEADING
According to the National Cancer Institute, no large-scale trials of antineoplastons have been conducted, and no randomized or controlled trials with comparison to a placebo have been performed. Existing evidence of the drug effectiveness is therefore inconclusive. https://www.cancer.gov/about-cancer/treatment/cam/hp/antineoplastons-pdq
Written by 4ABE6203F10279A89C2A3C09E70B746A68D327698E0FC5F06B79365FFE86469B
Participant Details
Original Tweet
Tweet embedding is no longer reliably available, due to the platform's instability (in terms of both technology and policy). If the Tweet still exists, you can view it here: https://twitter.com/foo_bar/status/1706412519810879591
Please note, though, that you may need to have your own Twitter account to access that page. I am currently exploring options for archiving Tweet data in a post-API context.
All Information
- ID - 1706428693956984985
- noteId - 1706428693956984985
- participantId -
- noteAuthorParticipantId - 4ABE6203F10279A89C2A3C09E70B746A68D327698E0FC5F06B79365FFE86469B Participant Details
- createdAtMillis - 1695679279203
- tweetId - 1706412519810879591
- classification - MISINFORMED_OR_POTENTIALLY_MISLEADING
- believable -
- harmful -
- validationDifficulty -
- misleadingOther - 0
- misleadingFactualError - 0
- misleadingManipulatedMedia - 0
- misleadingOutdatedInformation - 0
- misleadingMissingImportantContext - 1
- misleadingUnverifiedClaimAsFact - 1
- misleadingSatire - 0
- notMisleadingOther - 0
- notMisleadingFactuallyCorrect - 0
- notMisleadingOutdatedButNotWhenWritten - 0
- notMisleadingClearlySatire - 0
- notMisleadingPersonalOpinion - 0
- trustworthySources - 1
- summary
- According to the National Cancer Institute, no large-scale trials of antineoplastons have been conducted, and no randomized or controlled trials with comparison to a placebo have been performed. Existing evidence of the drug effectiveness is therefore inconclusive. https://www.cancer.gov/about-cancer/treatment/cam/hp/antineoplastons-pdq
Note Status History
| createdAt | timestampMillisOfFirstNonNMRStatus | firstNonNMRStatus | timestampMillisOfCurrentStatus | currentStatus | timestampMillisOfLatestNonNMRStatus | mostRecentNonNMRStatus | participantId |
| 2023-09-25 22:01:19 UTC (1695679279203) |
1969-12-31 23:59:59 UTC (-1) |
2023-09-26 02:11:34 UTC (1695694294267) |
NEEDS_MORE_RATINGS | 1969-12-31 23:59:59 UTC (-1) |
Note Ratings
| rated at | rated by | |
| 2023-09-25 19:25:33 -0500 | Rating Details | |
| 2023-09-25 19:19:20 -0500 | Rating Details | |
| 2023-09-25 19:12:48 -0500 | Rating Details | |
| 2023-09-25 19:12:22 -0500 | Rating Details | |
| 2023-09-25 19:10:56 -0500 | Rating Details | |
| 2023-09-25 19:06:10 -0500 | Rating Details | |
| 2023-09-25 17:56:30 -0500 | Rating Details | |
| 2023-09-25 17:48:40 -0500 | Rating Details | |
| 2023-09-25 17:43:14 -0500 | Rating Details | |
| 2023-09-25 17:37:35 -0500 | Rating Details | |
| 2023-09-25 17:13:16 -0500 | Rating Details | |
| 2023-09-25 17:05:21 -0500 | Rating Details | |
| 2023-09-26 14:06:19 -0500 | Rating Details | |
| 2023-09-26 12:45:33 -0500 | Rating Details | |
| 2023-09-26 12:32:32 -0500 | Rating Details | |
| 2023-09-26 07:28:13 -0500 | Rating Details | |
| 2023-09-26 06:08:42 -0500 | Rating Details | |
| 2023-09-26 05:37:12 -0500 | Rating Details | |
| 2023-09-26 05:27:06 -0500 | Rating Details | |
| 2023-09-26 05:01:41 -0500 | Rating Details | |
| 2023-09-26 03:35:55 -0500 | Rating Details | |
| 2023-09-26 01:31:38 -0500 | Rating Details | |
| 2023-09-26 01:12:24 -0500 | Rating Details | |
| 2023-09-26 00:54:12 -0500 | Rating Details | |
| 2023-09-26 00:37:16 -0500 | Rating Details | |
| 2023-09-26 00:23:55 -0500 | Rating Details | |
| 2023-09-26 00:15:35 -0500 | Rating Details | |
| 2023-09-26 00:07:23 -0500 | Rating Details | |
| 2023-09-25 23:24:18 -0500 | Rating Details | |
| 2023-09-25 22:43:26 -0500 | Rating Details | |
| 2023-09-25 22:24:13 -0500 | Rating Details | |
| 2023-09-25 22:16:33 -0500 | Rating Details | |
| 2023-09-25 21:41:55 -0500 | Rating Details | |
| 2023-09-25 21:33:56 -0500 | Rating Details | |
| 2023-09-25 21:33:12 -0500 | Rating Details | |
| 2023-09-25 21:21:02 -0500 | Rating Details | |
| 2023-09-25 21:10:41 -0500 | Rating Details | |
| 2023-09-25 21:10:01 -0500 | Rating Details | |
| 2023-09-25 20:46:24 -0500 | Rating Details | |
| 2023-09-25 20:43:45 -0500 | Rating Details | |
| 2023-09-25 20:29:22 -0500 | Rating Details | |
| 2023-09-25 20:09:48 -0500 | Rating Details | |
| 2023-09-25 20:08:19 -0500 | Rating Details | |
| 2023-09-25 19:57:41 -0500 | Rating Details | |
| 2023-09-25 19:36:45 -0500 | Rating Details | |
| 2023-09-29 00:06:00 -0500 | Rating Details | |
| 2023-09-26 11:28:22 -0500 | Rating Details | |
| 2023-11-26 16:34:14 -0600 | Rating Details | |
| 2023-11-26 15:07:56 -0600 | Rating Details |